

March 9, 2017



## Heat Biologics to Present at 29th Annual ROTH Conference

DURHAM, N.C., March 09, 2017 (GLOBE NEWSWIRE) -- [Heat Biologics, Inc.](http://www.heatbio.com) ("Heat") (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient's immune system against cancer, announced that Jeff Wolf, Heat's Founder and Chief Executive Officer, will present at the 29<sup>th</sup> Annual ROTH Conference in Newport Beach, CA on Monday, March 13, 2017, at 5:30 p.m. Pacific Time.

The link to the live audio webcast and replay of the presentation may be accessed on Heat's corporate website at <http://ir.heatbio.com/events-presentations>. The webcast will be archived on the company's website for a period of three months.

### ***About Heat Biologics, Inc.***

Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient's immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat's highly specific T cell-stimulating therapeutic vaccine platform technologies, *ImPACT* and *ComPACT*, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ "killer" T cells (one of the human immune system's most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients' immune response. Currently, Heat is conducting a Phase 1b trial with HS-110 (viagenpumatucl-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).

Heat's wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat's gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.

For more information, please visit [www.heatbio.com](http://www.heatbio.com).

Contact:  
Jennifer Almond  
Investor and Media Relations  
919-240-7133  
[Investorrelations@heatbio.com](mailto:Investorrelations@heatbio.com)



Source: Heat Biologics